GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback